# Fatty liver disease (NAFLD / MASLD)

Condition · id `cardio:nafld` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Fatty Liver Disease; MASLD; Metabolic dysfunction-associated steatotic liver disease; NAFLD; Nonalcoholic fatty liver disease

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A condition in which too much fat builds up in the liver in people who do not drink heavy amounts of alcohol. It is now often called metabolic dysfunction-associated steatotic liver disease (MASLD) and used to be called nonalcoholic fatty liver disease (NAFLD). It usually has few or no symptoms. It is more likely in people with obesity, metabolic syndrome or type 2 diabetes.

## Technical summary

MeSH descriptor D065626 (Non-alcoholic Fatty Liver Disease) is recorded as a broad match, because MedlinePlus now uses the newer name MASLD and this atlas has not compared the two sets of criteria. MASH, formerly NASH, is the form with inflammation and liver damage. The evidence recorded here is descriptive.

## Claims, with the population each applies to

## Context: People with metabolic syndrome or fatty liver disease (MedlinePlus and NIDDK patient pages)

Recipient: Mixed recipients; Population: People with metabolic syndrome or steatotic (fatty) liver disease, as described by MedlinePlus, NIDDK and MeSH. The liver page says children can also get it.; Care setting: Not stated; patient information pages; Geography: Not stated; United States federal health agencies; Life stage: Mostly adults; the liver page says it is more common in middle-aged or older people although children can also get it; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (descriptive page)

### NIDDK says that certain health conditions and diseases, including obesity, metabolic syndrome and type 2 diabetes, make a person more likely to develop NAFLD.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Mixed recipients; Population: People with metabolic syndrome or steatotic (fatty) liver disease, as described by MedlinePlus, NIDDK and MeSH. The liver page says children can also get it.; Care setting: Not stated; patient information pages; Geography: Not stated; United States federal health agencies; Life stage: Mostly adults; the liver page says it is more common in middle-aged or older people although children can also get it; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (descriptive page)
- Limitations: A patient-information page. It names conditions that make NAFLD more likely and gives no size for the risk. A patient-information or vocabulary source: it describes the condition and the direction of any risk. It gives no size for the risk, no time frame and no comparison group, and it is not clinical advice.
- Last checked: 2026-10-30
- Sources:
  1. Supports: NIDDK: Nonalcoholic Fatty Liver Disease (NAFLD) & NASH (Webpage, edition NIDDK page fetched 2026-10-30. The review date shown on the page itself was not recorded.) <https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash>
     Locator: Symptoms & Causes. Retrieved 2026-10-30T19:19:46Z. Source state: Current. Version fingerprint: 8461101028cc8a6fe2a5ae378516742d7f0fe30750b3113ad14d005be7544519.
     How it applies: NIDDK on conditions linked to NAFLD.

### MedlinePlus says MASLD is the most common chronic (long-term) liver disease, because of increasing rates of obesity, type 2 diabetes and high cholesterol.

- Category: Burden
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Mixed recipients; Population: People with metabolic syndrome or steatotic (fatty) liver disease, as described by MedlinePlus, NIDDK and MeSH. The liver page says children can also get it.; Care setting: Not stated; patient information pages; Geography: Not stated; United States federal health agencies; Life stage: Mostly adults; the liver page says it is more common in middle-aged or older people although children can also get it; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (descriptive page)
- Limitations: A statement on a patient-information page with no count, year or country. It names MASLD, the newer name; whether the same holds for the NAFLD heading in MeSH is not stated.
- Last checked: 2026-10-30
- Sources:
  1. Supports: Steatotic Liver Disease | Fatty Liver Disease (MedlinePlus health topic) (Webpage, edition Page fetched 2026-10-30. The request to fattyliverdisease.html was answered with this page, whose own URL line reads steatoticliverdisease.html.) <https://medlineplus.gov/steatoticliverdisease.html>
     Locator: Summary, Who is more likely to develop steatotic liver disease?, para after list. Retrieved 2026-10-30T19:19:43Z. Source state: Current. Version fingerprint: a6c075e913bfec6d9500517e7299f1bda46f3a206c4b67ed7865f3d1b807db5c.
     How it applies: MedlinePlus on how common MASLD is.

### MedlinePlus says steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in the liver, and that metabolic dysfunction-associated steatotic liver disease (MASLD) is the type that is not caused by heavy alcohol use and used to be called nonalcoholic fatty liver disease. NIDDK uses the older name and describes nonalcoholic fatty liver disease (NAFLD) as a condition in which fat builds up in the liver. MedlinePlus says MASLD usually has few or no symptoms. The MeSH scope note describes a fatty liver finding without excessive alcohol consumption.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Mixed recipients; Population: People with metabolic syndrome or steatotic (fatty) liver disease, as described by MedlinePlus, NIDDK and MeSH. The liver page says children can also get it.; Care setting: Not stated; patient information pages; Geography: Not stated; United States federal health agencies; Life stage: Mostly adults; the liver page says it is more common in middle-aged or older people although children can also get it; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (descriptive page)
- Limitations: The MeSH heading and the NIDDK page use the older name NAFLD; the newer MedlinePlus page uses MASLD. This atlas does not compare the two sets of criteria. A patient-information or vocabulary source: it describes the condition and the direction of any risk. It gives no size for the risk, no time frame and no comparison group, and it is not clinical advice.
- Last checked: 2026-10-30
- Sources:
  1. Supports: MeSH scope note for descriptor D065626 (Non-alcoholic Fatty Liver Disease) (Dataset, edition MeSH linked-data record of the preferred concept M0533561 of descriptor D065626, fetched 2026-10-30. The scope note is on this concept record, not on the descriptor record.) <https://id.nlm.nih.gov/mesh/M0533561>
     Locator: scopeNote.@value. Retrieved 2026-10-30T19:22:24Z. Source state: Current. Version fingerprint: 08a55f15b8346a30ee07fe8675338e274b7279f8e97c4a3b8adf974a336eee09.
     How it applies: MeSH scope note for the descriptor.
  2. Supports: Steatotic Liver Disease | Fatty Liver Disease (MedlinePlus health topic) (Webpage, edition Page fetched 2026-10-30. The request to fattyliverdisease.html was answered with this page, whose own URL line reads steatoticliverdisease.html.) <https://medlineplus.gov/steatoticliverdisease.html>
     Locator: Summary, What is steatotic liver disease? and What is MASLD?. Retrieved 2026-10-30T19:19:43Z. Source state: Current. Version fingerprint: a6c075e913bfec6d9500517e7299f1bda46f3a206c4b67ed7865f3d1b807db5c.
     How it applies: MedlinePlus definitions and names.
  3. Supports: NIDDK: Nonalcoholic Fatty Liver Disease (NAFLD) & NASH (Webpage, edition NIDDK page fetched 2026-10-30. The review date shown on the page itself was not recorded.) <https://www.niddk.nih.gov/health-information/liver-disease/nafld-nash>
     Locator: Definition & Facts. Retrieved 2026-10-30T19:19:46Z. Source state: Current. Version fingerprint: 8461101028cc8a6fe2a5ae378516742d7f0fe30750b3113ad14d005be7544519.
     How it applies: NIDDK definition of NAFLD.

## Connected pages

- Filed under this front: Kidney and metabolic care (`cardio:front-kidney-and-metabolic-care`)
- Metabolic syndrome is one of the conditions linked to fatty liver disease: Metabolic syndrome (`cardio:metabolic-syndrome`)
- Type 2 diabetes is one of the conditions linked to fatty liver disease: Type 2 diabetes (`cardio:type-2-diabetes`)
- Obesity is one of the conditions linked to fatty liver disease: Obesity (`core:obesity`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 8 registry trials

## Provenance

Content hash: 31c1028b2ea258006ae95d9470eb08cd54ed40d999b389df88193635ff056bbb
Last substantive edit: 2026-10-30
Evidence last checked: 2026-10-30
